Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Free Cash Flow (2019 - 2025)

BridgeBio Pharma's Free Cash Flow history spans 7 years, with the latest figure at -$56.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 71.2% year-over-year to -$56.5 million; the TTM value through Dec 2025 reached -$447.0 million, up 14.31%, while the annual FY2025 figure was -$447.0 million, 14.31% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$56.5 million at BridgeBio Pharma, up from -$110.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $75.3 million in Q2 2024 and bottomed at -$220.2 million in Q1 2024.
  • The 5-year median for Free Cash Flow is -$126.0 million (2021), against an average of -$120.7 million.
  • The largest annual shift saw Free Cash Flow crashed 245.12% in 2023 before it soared 166.43% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$123.7 million in 2021, then grew by 27.86% to -$89.3 million in 2022, then tumbled by 38.96% to -$124.0 million in 2023, then tumbled by 57.99% to -$196.0 million in 2024, then surged by 71.2% to -$56.5 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Free Cash Flow are -$56.5 million (Q4 2025), -$110.6 million (Q3 2025), and -$80.3 million (Q2 2025).